Cross-posted with permission from Devex.com.
The World Health Organization’s first global report on diabetes released this month highlights the disease’s “alarming surge” with rates that have quadrupled in fewer than three decades. The report reminds us that essential diabetes medicines and health technologies, including lifesaving insulin, are available in only one in three of the world’s poorest countries.
Post updated December 19, 2014.
This post originally appeared on the Systems for Improved Access to Pharmaceuticals and Services (SIAPS) Program Blog. Funded by the US Agency for International Development (USAID) and implemented by Management Sciences for Health (MSH), SIAPS works to assure the availability of quality pharmaceutical products and effective pharmaceutical services to achieve desired health outcomes.
Every year, billions of US dollars’ worth of medicines are purchased by or through international procurement agencies, NGOS–such as UNICEF, UNITAID, The Global Fund, Médecins Sans Frontières (MSF)–and governments for use in developing countries. The World Health Organization’s (WHO's) PreQualification of Medicines Programme (PQP) helps ensure that these medicines meet acceptable standards of quality, safety and efficacy.